Medigen Vaccine Biologics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	594.96	605.64	389.62	365.04	3,281	11.51
Revenue Growth (YoY)	-8.21%	55.44%	6.73%	-88.87%	28413.03%	927.41%
Cost of Revenue	264.82	209.22	159.4	577.64	975.96	3.87
Gross Profit	330.14	396.42	230.22	-212.6	2,305	7.64
Selling, General & Admin	294.83	320.58	243.44	183.67	148.21	91.96
Research & Development	202.94	221.51	1,201	1,140	1,193	679.56
Operating Expenses	497.78	542.09	1,444	1,324	1,341	771.52
Operating Income	-167.64	-145.67	-1,214	-1,536	963.73	-763.88
Interest Expense	-8.79	-18.89	-37.57	-26.89	-6.02	-16.42
Interest & Investment Income	32.1	46.25	83.28	7.61	2.74	1.48
Currency Exchange Gain (Loss)	-14.42	38.35	-0.33	28.86	7.52	4.15
Other Non Operating Income (Expenses)	1.51	-1.62	8.61	32.25	-0.07	0.19
EBT Excluding Unusual Items	-157.23	-81.57	-1,160	-1,494	967.9	-774.49
Gain (Loss) on Sale of Investments	-	-	-	-	-	-0.06
Gain (Loss) on Sale of Assets	-8.43	0.41	-	-	-	19.73
Other Unusual Items	0.01	0.7	-	19.86	442.36	80.54
Pretax Income	-165.64	-80.47	-1,160	-1,475	1,410	-674.28
Net Income	-165.64	-80.47	-1,160	-1,475	1,410	-674.28
Net Income to Common	-165.64	-80.47	-1,160	-1,475	1,410	-674.28
Shares Outstanding (Basic)	329	329	328	323	319	277
Shares Outstanding (Diluted)	329	329	328	323	321	277
Shares Change (YoY)	0.01%	0.10%	1.50%	0.73%	15.82%	20.08%
EPS (Basic)	-0.50	-0.24	-3.53	-4.56	4.42	-2.43
EPS (Diluted)	-0.50	-0.24	-3.53	-4.56	4.39	-2.43
Free Cash Flow	-28.29	6.46	-521.25	-1,353	446.26	-689.22
Free Cash Flow Per Share	-0.09	0.02	-1.59	-4.18	1.39	-2.49
Gross Margin	55.49%	65.45%	59.09%	-58.24%	70.25%	66.36%
Operating Margin	-28.18%	-24.05%	-311.54%	-420.85%	29.37%	-6638.40%
Profit Margin	-27.84%	-13.29%	-297.68%	-403.95%	42.98%	-5859.74%
Free Cash Flow Margin	-4.75%	1.07%	-133.78%	-370.64%	13.60%	-5989.55%
EBITDA	-47.12	-26.16	-1,098	-1,423	1,072	-653.8
EBITDA Margin	-7.92%	-4.32%	-281.86%	-	32.67%	-
D&A For EBITDA	120.51	119.5	115.64	112.91	108.34	110.08
EBIT	-167.64	-145.67	-1,214	-1,536	963.73	-763.88
EBIT Margin	-28.18%	-24.05%	-	-	29.37%	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.